← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA3310.7x15.6x19.6x
EV / LTM revenue561.8x2.9x5.4x
Premium to unaffected price8928%42%63%
Premium to 30-day VWAP2237%49%74%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
011212010: 5 deals, 2 clean on every measure201052011: 8 deals, 4 clean on every measure201182012: 13 deals, 5 clean on every measure2012132013: 9 deals, 4 clean on every measure201392014: 12 deals, 7 clean on every measure2014122015: 4 deals, 1 clean on every measure201542016: 9 deals, 7 clean on every measure201692017: 8 deals, 6 clean on every measure201782018: 10 deals, 2 clean on every measure2018102019: 10 deals, 4 clean on every measure2019102020: 11 deals, 4 clean on every measure2020112021: 10 deals, 8 clean on every measure2021102022: 12 deals, 8 clean on every measure2022122023: 21 deals, 9 clean on every measure2023212024: 10 deals, 6 clean on every measure2024102025: 13 deals, 7 clean on every measure2025132026: 11 deals, 5 clean on every measure202611
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 17.6x median across 26 dealsHealthcare17.6xn=26Materials: 9.7x median across 7 dealsMaterials9.7xn=7
Deals by sector
Healthcare: 151 dealsHealthcare151Materials: 25 dealsMaterials25
Deals by buyer type
Financial sponsor: 8 dealsFinancial sponsor8Strategic: 176 dealsStrategic176Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 109 dealsUnclassified109
Deals by enterprise value
Under $250m: 67 dealsUnder $250m67$250m to $1bn: 28 deals$250m to $1bn28$1bn to $5bn: 48 deals$1bn to $5bn48$5bn to $20bn: 27 deals$5bn to $20bn27Over $20bn: 4 dealsOver $20bn4Not computed: 2 dealsNot computed2
Deals by industry code
Business Services & Software: 229 dealsBusiness Services & Sof…229Depository Institutions: 208 dealsDepository Institutions208Chemicals, Pharmaceuticals & Allied Products: 176 dealsChemicals, Pharmaceutic…176Electronics & Electrical Equipment: 129 dealsElectronics & Electrica…129Instruments, Medical Devices & Optical Goods: 97 dealsInstruments, Medical De…97Holding & Other Investment Offices: 82 dealsHolding & Other Investm…82Oil & Gas Extraction: 76 dealsOil & Gas Extraction76Industrial Machinery & Computers: 66 dealsIndustrial Machinery & …66Electric, Gas & Sanitary Services: 66 dealsElectric, Gas & Sanitar…66Communications: 64 dealsCommunications64
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Spectrum Pharmaceuticals Inc
2023-04-24 · Public merger · $0.20 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Assertio Holdings, Inc.
Strategic
Healthcare$14mn.a.0.5x
65%
DEFM14A
Includes stock
Satsuma Pharmaceuticals, Inc.
2023-04-16 · Take-private · $0.91 a share
Shin Nippon Biomedical Laboratories, Ltd.
Strategic
Healthcare-$11mn.a.n.a.
n.a.
SC 13E3
All cash
Prometheus Biosciences, Inc.
2023-04-15 · Public merger · $200.00 a share
Held out of the multiples: EV / LTM revenue 2198.1x above 60x
Merck & Co., Inc.
Strategic
Healthcare$8.8bnn.a.2198.1x
75%
DEFM14A
All cash
Heska Corp
2023-03-31 · Public merger · $120.00 a share
Antech Diagnostics, Inc.
Strategic
Healthcare$1.2bnn.a.4.6x
23%
DEFM14A
All cash
Seagen Inc.
2023-03-12 · Public merger · $229.00 a share
Pfizer Inc.
Strategic
Healthcare$41bnn.a.20.9x
42%
DEFM14A
All cash
CalciMedica, Inc.
2022-11-21 · Public merger · $0.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Inc.
Strategic
Healthcare-$33mn.a.n.a.
n.a.
DEFM14A
Includes stock
Opiant Pharmaceuticals, Inc.
2022-11-13 · Public merger · $20.00 a share
Indivior Inc.
Strategic
Healthcare$80mn.a.3.6x
111%
DEFM14A
All cash
Myovant Sciences Ltd.
2022-10-23 · Take-private · $27.00 a share
Board book on file →
Sumitomo Pharma Co., LTD.
Strategic
Healthcare$2.2bnn.a.6.7x
50%
48% to VWAP
SC 13E3
All cash
Old Ayala, Inc
2022-10-18 · Public merger · $4.75 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Advaxis, Inc.
Strategic
Healthcare$59mn.a.34.6x
n.a.
DEFM14A
Includes stock
Coeptis Therapeutics Inc.
2022-09-30 (filed) · Public merger · $10.00 a share
Bull Horn Holdings Corp.
Strategic
Healthcare$383mn.a.n.a.
n.a.
DEFM14A
All cash
Aerie Pharmaceuticals Inc
2022-08-22 · Public merger · $15.25 a share
Alcon Research, LLC
Strategic
Healthcare$568mn.a.2.7x
39%
DEFM14A
All cash
Global Blood Therapeutics, Inc.
2022-08-07 · Public merger · $68.50 a share
Pfizer Inc.
Strategic
Healthcare$4.4bnn.a.18.5x
102%
110% to VWAP
DEFM14A
All cash
Tyme Technologies, Inc.
2022-07-03 · Public merger · $2.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Syros Pharmaceuticals, Inc.
Strategic
Healthcare$353mn.a.n.a.
n.a.
DEFM14A
Includes stock
Ocean Bio Chem Inc
2022-06-21 · Public merger · $13.08 a share
OneWater Marine Inc.
Strategic
Materials$122m10.6x1.9x
121%
DEFM14C
All cash
Biohaven Pharmaceutical Holding Co Ltd.
2022-05-09 · Public merger · $148.50 a share
Pfizer Inc.
Strategic
Healthcare$11bnn.a.14.3x
79%
DEFM14A
All cash
Pro Farm Group, Inc.
2022-03-16 · Public merger · $0.35 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Bioceres Crop Solutions Corp.
Strategic
Materials$76mn.a.1.7x
n.a.
DEFM14A
Includes stock
Renewable Energy Group, Inc.
2022-02-27 · Public merger · $61.50 a share
Chevron Corporation
Strategic
Materials$2.8bn9.7x1.0x
32%
DEFM14A
All cash
Arena Pharmaceuticals Inc
2021-12-12 · Public merger · $100.00 a share
Pfizer Inc.
Strategic
Healthcare$5.4bnn.a.n.a.
100%
DEFM14A
All cash
Rogers Corp
2021-11-01 · Public merger · $277.00 a share
DuPont de Nemours, Inc., Inc.
Strategic
Healthcare$5.0bn27.5x5.4x
33%
46% to VWAP
DEFM14A
All cash
Kraton Corp
2021-09-27 · Public merger · $46.50 a share
DL Chemical Co., Ltd.
Strategic
Healthcare$2.4bnn.a.n.a.
n.a.
DEFM14A
All cash
Kadmon Holdings, Inc.
2021-09-07 · Public merger · $9.50 a share
Held out of the multiples: EV / LTM revenue 719.4x above 60x
Nano Terra, Inc.
Strategic
Healthcare$1.4bnn.a.719.4x
79%
DEFM14A
All cash
Kindred Biosciences, Inc.
2021-06-15 · Public merger · $9.25 a share
Elanco Animal Health Incorporated
Strategic
Healthcare$376mn.a.8.6x
n.a.
DEFM14A
All cash
Ferro Corp
2021-05-11 · Public merger · $22.00 a share
PMHC II Inc.
Strategic
Healthcare$2.1bnn.a.2.1x
25%
DEFM14A
All cash
Chiasma, Inc
2021-05-04 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Amryt Pharma plc
Strategic
Healthcare$33mn.a.30.3x
n.a.
DEFM14A
Includes stock
W R Grace & Co
2021-04-26 · Take-private · $70.00 a share
Board book on file →
Not named in the filing
Strategic
Materials$6.3bnn.a.3.6x
59%
54% to VWAP
SC 13E3
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More